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Abstract
We hypothesized that human genes differ by their sensitivity to ultraviolet (UV)
exposure. We used somatic mutations detected by genome‐wide screens in mela-
noma and reported in the Catalog Of Somatic Mutations In Cancer. As a measure of
UV sensitivity, we used the number of silent mutations generated by C>T transitions
in pyrimidine dimers of a given transcript divided by the number of potential sites
for this type of mutations in the transcript. We found that human genes varied by
UV sensitivity by two orders of magnitude. We noted that the melanoma‐associated
tumor suppressor gene CDKN2A was among the top five most UV‐sensitive genes in
the human genome. Melanoma driver genes have a higher UV‐sensitivity compared
with other genes in the human genome. The difference was more prominent for
tumor suppressors compared with oncogene. The results of this study suggest that
differential sensitivity of human transcripts to UV light may explain melanoma
specificity of some driver genes. Practical significance of the study relates to the fact
that differences in UV sensitivity among human genes need to be taken into con-
sideration whereas predicting melanoma‐associated genes by the number of somatic
mutations detected in a given gene.
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1 | INTRODUCTION
Cutaneous melanoma shows the largest number of somatic muta-
tions per tumor compared with other cancer types (Martincorena &
Campbell, 2015). The mutational spectrum of melanoma mutations is
characterized by a ultraviolet (UV)‐mutational signature (Alexandrov,
Nik‐Zainal, Wedge, Campbell, & Stratton, 2013; Petljak et al., 2019).
The single most prevalent type of mutations associated with UV
signature is cytosine (C)→thymine (T) at dipyrimidine sites through
deamination of cytosine‐containing cyclobutane pyrimidine dimers
(Ikehata & Ono, 2011).
Silent mutations detected in tumor samples, including melanoma,
are the second (after missense) most common type of somatic var-
iants. Silent mutations do not change the amino acid sequence. Even
though there are anecdotal examples of functionality of silent mu-
tations (Bali & Bebok, 2015; Pagani, Raponi, & Baralle, 2005), the
absolute majority of them are expected to be functionally neutral
which makes them highly suitable for assessing gene sensitivity to
environmental mutagens. Even though mutations in noncoding re-
gions are also mostly functionally neutral they cannot be used for
comparative analysis of human transcripts.
The Catalog Of Somatic Mutations In Cancer (COSMIC; Forbes
et al., 2010; Tate et al., 2019) is the largest well annotated collection
of somatic variants detected in tumor samples. A considerable frac-
tion of COSMIC data is generated by whole genome screens, making
them suitable for comparative analysis of mutability of human genes.
A number of local chromosomal features including nucleosomes,
transcription factor binding sites, chromatin accessibility, replication
timing, and DNA strand have been shown to influence mutation rate
(Gonzalez‐Perez, Sabarinathan, & Lopez‐Bigas, 2019; Morganella
et al., 2016; Tomkova, Tomek, Kriaucionis, & Schuster‐Bockler,
2018). These studies suggest, therefore, that human genes may
possess intrinsically different UV sensitivity.
The goal of this study was to assess the variation in UV sensi-
tivity among human genes and to compare UV sensitivity of mela-
noma drivers with UV sensitivity of other genes in the human
genome.
2 | MATERIALS AND METHODS
2.1 | Data
We used somatic mutations reported in the COSMIC (Forbes
et al., 2010; Tate et al., 2019). The database was accessed December
26, 2019. To account for possible bias related to unequal targeting of
different genes, we used only confirmed somatic mutations from
whole genome mutational screens. Mutational data from 15 mela-
noma studies were used in the analysis (Abaan et al., 2013; Aydin
et al., 2014; Berger et al., 2012; Dahlman et al., 2012; Furney et al.,
2012; Hodis et al., 2012; Krautham mer, Kong, Bacchiocchi
et al., 2015; Krauthammer, Kong, Ha et al., 2012; Kuckein, 1980;
Nikolaev et al., 2011; Pleasance et al., 2010; Sanborn et al., 2015;
Shain et al., 2015; Wagle et al., 2014; Wei et al., 2011). In total, those
studies produced 334,625 unique mutations detected in 733
samples.
2.2 | Estimations of the number of potential
mutational sites for UV‐induced mutations
We used transcript IDs provided by COSMIC to retrieve corre-
sponding nucleotide sequences from the Consensus coding
sequence database (Pujar et al., 2018). In total 38,721 unique
transcripts linked to 17,924 human genes were identified and
used in the analysis. Since UV‐mutational signature is context
dependent (Lindberg, Bostrom, Elliott, & Larsson, 2019), and the
majority of UV‐induced substitutions occur in di‐pyrimidines
(Alexandrov et al., 2013; Petljak et al., 2019), we have identified
the number of C>Ts for each of the 16 possible trinucleotides
with “C” in the middle. We have also estimated numbers of
potential sites where C>T transition in pyrimidine dimers if it
happened would produce a silent mutation. These estimates
provided us with the numbers of potential sites for UV‐induced
silent mutations for each individual transcript. To estimate the
observed numbers of UV‐induced (C>T transitions in pyrimidine
dimers) silent mutations we have used COSMIC silent mutations
detected by whole genome screens. The data on the number
of potential sites and observed number of silent mutations in
trinucleotides can be found in supplementary materials
(Table S1).
2.3 | Estimation of UV sensitivity
Each human transcript was scanned across all possible trinucleotides
with one nucleotide step, which allowed us to identify all trinucleo-
tides in the transcript with “C” in the middle. Among trinucleotides
with “C” in the middle we identified trinucleotides where substitution
of middle/core “C” to “T” leads to a silent mutation. That gives us the
number of potential sites for silent mutation‐producing C>T transi-
tions for each of 16 possible trinucleotides in each transcript. As a
quantitative measure of UV‐sensitivity of a transcript we have used
the ratio of the observed number of silent mutation producing C>T
substitutions in trinucleotides with pyrimidine dimers: ACC, ACT,
CCA, CCC, CCG, CCT, GCC, GCT, TCA, TCC, TCG, and TCT to the
number of potential sites in individual transcripts for those type of
mutations. Thus UV sensitivity was estimated by using the following
formula: UVs(t) =Nobs(C>T silent)/Nsites(C>T silent): where UVs(t) is a UV
sensitivity of a given transcript, Nobs(C>T silent)—the observed number
of silent mutations generated by C>T substitutions in pyrimidine
dimers in a given transcript, Nsites(C>T silent)—the number potential
sites in a given transcript where C>T substitutions in pyrimidine di-
mers would produce silent mutations. C>T substitutions in trinu-
cleotides without pyrimidine dimers: ACA, ACG, GCA, and GCG were
considered as not UV‐induced and were analyzed separately.
3 | RESULTS
3.1 | Human genes differ by UV‐sensitivity
Figure 1 shows the distribution of human transcripts by densities of
UV‐induced and non‐UV‐induced C>T substitutions. For UV‐induced
mutations average transcript mutability was 0.02428 ± 0.0001 and
for non‐UV‐induced mutations it was 0.0025 ± 0.00002 (t test =
150.5, N = 77,442, p = 2.2 × 10−86). Human transcripts were categor-
ized by mutational densities using 0.001 increment, so the first group
included genes with estimated density between 0 and 0.001, the
second group included genes with estimated density 0.001‐0.002 and
so on. We observed drastic differences between the two distribu-
tions the density of non‐UV‐induced C>T mutations clustering near
zero and the density of UV‐induced C>T transitions clustering near
0.01. A relatively large number of observations for UV‐induced mu-
tations in the density group between 0 and 0.001 (solid diamond) can
be a result of insufficient statistical power for estimation of muta-
tional densities for small human genes. We noted that transcripts
without reported silent mutations were two times smaller compared
with the genes with at least one reported silent mutation: 951 ± 6
versus 1,924 ± 12. It is likely, therefore, that currently available
sample size may be too small to estimate of the densities of silent
mutations in small genes reliably.
The top 10 most UV‐sensitive genes listed from higher to lower
UV‐sensitivity were CDKN2A, PCP4, POM121L12, STATH, OR13C4,
S100Z, OR4C3, HIGD1A, OR13C8, and OR4K2. Table S1 shows the
assessed UV‐sensitivities for individual transcripts.
3.2 | UV‐induced mutations in melanoma driver
genes
Figure 2 shows the distribution of genes by UV sensitivity. We used
the same categorization of transcripts by UV sensitivity (0.001 in-
crement) as for Figure 1. The majority of melanoma drivers have a
higher than average UV sensitivity. CDKN2A is an extreme example:
this gene shows 20 times higher UV sensitivity compared with overall
average UV sensitivity.
3.3 | Nucleotide context analysis
It is known that mutability is generally context dependent (Rogozin,
Malyarchuk, Pavlov, & Milanesi, 2005). For that reason, for the tran-
script level analysis we estimated UV sensitivity of individual transcripts
by taking into account nucleotide context. Figure 3 summarizes the
results of the analysis. Melanoma drivers were analyzed separately from
F IGURE 1 The distribution of human transcripts by densities of UV‐induced (open diamonds) and not UV‐induced (solid circles) silent
mutations. Two distributions are drastically different with the average density of UV‐induced silent mutations being about 10 times higher
compared with the average density of non‐UV‐induced silent mutations. In total, 97,435 mutations detected in 733 samples from 15 studies
were used in the analysis. UV, ultraviolet
other cancer genes. Melanoma drivers were then compared with all
human genes. We found that distributions of the observed numbers of
silent mutations generated by the core C>T substitutions across 16
genotypes are similar across three groups of genes (Figure 3, upper
panel). The distributions of the number of potential sites for silent
mutations resulting from C>T transitions in core “Cs” were also similar
between three groups (middle panel, Figure 3d–f). However, the relative
densities of silent mutations among melanoma drivers was higher
compared with the density of silent mutations for other cancer genes, as
well as for all genes in the human genome (Figure 3g). We also com-
puted relative silent mutation densities using all human transcripts as a
reference group. If the relative density is close to one the mutational
density in the group of the genes is similar to a typical gene in the
human genome. For all known cancer‐related genes mutational den-
sities were similar to the average human gene (Figure 3h). However
melanoma drivers show a much higher density of silent mutation
(Figure 3i). This is true only for C>T transitions in pyrimidine dimers
(UV‐induced substitutions) while non‐UV‐induced substitutions (those
occurring in nonpyrimidine triplets: ACA, ACG, GCA, and GCG) do not
differ from the whole genome average (yellow horizontal line, Figure 3i).
3.4 | UV‐sensitivity of tumor suppressors and
oncogenes
We further investigated UV sensitivity of melanoma drivers by
subdividing them into tumor suppressors (TSs) and oncogenes. The
majority of functional mutations in tumor suppressors are expected
to be loss‐of‐function mutations whereas the majority of functional
mutations in oncogenes are expected to be gain‐of‐function muta-
tions. Since it is much easier to destroy a function by random mu-
tations than to generate a novel function, loss‐of‐function mutations
that are predominant in TS tend to occur at multiple sites. Gain‐of‐
function mutations, on the other hand, are more specific and tend to
occur at a single position. Therefore, one can expect that TSs will
show a stronger association with UV‐sensitivity compared with on-
cogenes. We estimated UV‐sensitivities of melanoma‐associated TSs
and melanoma oncogenes and compared them with UV sensitivities
of all known TSs and oncogenes. We used UniprotKB database an-
notations (UniProt, 2019) to identify human tumor suppressors and
oncogenes. Figure 4 shows the results of the analysis. The average
UV sensitivity of known melanoma TSs: CDKN2A, PTPRT, GRIN2A,
DCC, and GRM3 was 0.178 ± 0.042, which was significantly higher
than the overall average −0.024 ± 0.001, as well as the average UV
sensitivity of all TSs 0.024 ± 0.04: corresponding t tests were 3.6 and
3.8 and corresponding p‐values .0006 and .0002. Melanoma specific
and all‐cancer oncogenes showed similar UV sensitivities (Figure 4b).
3.5 | Partitioning of melanoma mutations by
mutational signatures
We used Mutational Signatures in Cancer (Diaz‐Gay et al., 2018) soft-
ware to classify melanoma mutations according to contributions of
F IGURE 2 The distribution of human transcripts by UV‐sensitivity. Dark gray circles indicate the number of transcripts in a given category of
UV sensitivity. Names of known melanoma genes are shown with the positions corresponding to their UV‐sensitivity. The gray vertical bar
indicates the average UV sensitivity for all human transcripts. UV, ultraviolet
known mutational signatures. All mutations detected by genome‐wide
screens were used in the analysis. We found that the absolute majority
of mutations (76.4%) are assigned to the signature 7—“UV light”
(Table 1). Aside from UV light, several other signatures were found
including age, POLE and alkylating agents. At the same time, the pro-
portion of C>T transitions in pyrimidine dimers (the type of mutations
we considered to be UV light‐induced) among all mutations was 80.1%.
The vast majority of mutations appear UV‐light related.
4 | DISCUSSION
We found a large variation in UV sensitivity among human tran-
scripts (Figures 1 and 2). Cyclin dependent kinase inhibitor 2A,
CDKN2A (transcripts ENST00000530628 and ENST00000579755)
was identified as a having a highest UV sensitivity. CDKN2A is a key
gene controlling cell cycle progression. CDKN2A regulates expres-
sion of TP53 (Foulkes, Flanders, Pollock, & Hayward, 1997; Zhao,
F IGURE 3 (a–c) The number of reported silent mutations in 16 possible trinucleotides with “C” in the middle for different categories of
genes. (d–f) The number of sites of silent mutations in 16 possible trinucleotides with “C” in the middle for different categories of genes. (g) The
numbers of silent mutations per site across trinucleotides across different gene categories. (h and i) Relative mutation densities in all COSMIC‐
defined cancer genes (h) and melanoma genes (i). For melanoma genes we separately analyzed non‐UV‐induced (light bars) and UV‐induced
(dark bars) C>T substitutions producing silent mutations. Horizontal lines shows averages for non‐UV‐induced (light gray) and UV‐induced (dark
gray) silent mutations. UV, ultraviolet
Choi, Lee, Bode, & Dong, 2016). TP53 plays a central role in cell
survival (Deben, Deschoolmeester, Lardon, Rolfo, & Pauwels, 2016;
Yamamoto & Iwakuma, 2018). Based on the role of CDKN2A in
regulation of cell cycle/apoptosis and its unusually high UV‐
sensitivity one can hypothesize that inactivation of CDKN2A by
UV‐induced mutations is often the first driving step in melanoma
development. Inactivation of CDKN2A will lead to a higher cell pro-
liferation and downregulation of apoptosis in the mutant clone. In-
creased cell proliferation and decreased apoptosis will accelerate
accumulation of mutations in other driver genes further driving
tumorigenesis.
We and others demonstrated that several germline polymorph-
isms in CDKN2A are associated with increased risk of melanoma
(Begg et al., 2005; Berwick et al., 2006; Orlow et al., 2007). Those
findings support the idea that loss‐of‐function somatic mutations in
CDKN2A may initiate melanoma. Since CDKN2A has extremely high
mutational sensitivity to UV‐light one can expect that loss‐of‐
function somatic mutations can be the first initiation event in mela-
noma development. On the other hand, the study by Martincorena
et al. (2015) found no positive selection for CDKN2A mutation in
normal skin suggesting that CDKN2A inactivation may also provide
selective advantage at later stages of clonal evolution.
Cancer‐associated genes can be roughly divided into the genes
with cancer‐specific effect and common (Pan‐Cancer) genes. TP53 is
a classic example of a common driver which is frequently mutated in
all‐cancer types. However, other drivers are found to be mutated
only in specific cancer types (e.g., CANT1 mutated in prostate cancers
only; Gerhardt et al., 2011). Since all‐cancer types have common
cancer‐related features including increase proliferation rate, sup-
pressed apoptosis, angiogenesis, and avoiding immune host response
(Hanahan & Weinberg, 2011; Pavlova & Thompson, 2016), the ex-
istence of cancer type‐specific drivers is rather puzzling. Several
explanations for existence of cancer‐specific driver genes have been
proposed. It is generally accepted that cancer specificity of driver
genes reflects biological differences between normal human tissues:
selective advantages somatic mutations depend on tissue
environment (Tiong & Yeang, 2018). Schaefer and Serrano (2016)
demonstrated that cancer/tissue specificity of drivers can be influ-
enced by environmental factors like viral infection which are fre-
quently tissue specific. Tissue specificity of drivers may also be
related to histone modifications and chromatin architecture (Lim,
Mun, Kim, & Kim, 2017). The results of our analysis suggest that
cancer specificity can be a result of differential sensitivity of human
genes to the cancer‐inducing mutagens. Differential sensitivity to
cancer‐inducing mutagen may act as a selective factor for the re-
cruitment of driver genes from the pool of the genes that potentially
could act as drivers. It is known that human genome contains a large
number of genes influencing cancer‐related functions. According to
the Gene Ontology database (accessed February 10, 2020) there are
778 genes modulating cell proliferation and 1,201 genes modulating
cell survival. Those and other genes modulating cancer‐related
functions can be considered as a pool of genes from which cancer‐
specific driver can be recruited. In case of melanoma, one can expect
that genes with a highest UV sensitivity will have a better chance to
be recruited as cancer drivers because they are more likely to get
mutated. The outlined reasoning is especially relevant to tumor
suppressors for which multiple sites for loss‐of‐function mutations
are available and UV exposure can produce them. Oncogenes, on the
other hand, can be activated by a mutation at a single site only and a
nucleotide substitution required for the gain‐of‐function mutation is
not necessarily a C>T transition in pyrimidine dimer which is a
principal target for UV exposure. A higher UV‐sensitivity of mela-
noma TS compared with melanoma oncogenes is consistent with the
idea that melanoma drivers are recruited by a tumor cell based on
their UV sensitivity. It does not mean, of course, that all melanoma
drivers will have high UV sensitivity. In fact UV sensitivity of many
known melanoma drivers including NRAS, TP53, KIT, and BRAF is
lower than average. Interestingly, all those drivers except TP53 are
oncogenes. TP53 has a dual nature and can act as tumor suppressor
or oncogene depending on the type of mutation it acquires
(Hainaut & Pfeifer, 2016). The higher UV‐sensitivity of melanoma TSs
can be related to the differences between TSs and other genes in the
F IGURE 4 UV sensitivity of tumor suppressors and oncogenes grouped by cancer specificity (melanoma versus all cancers). UV, ultraviolet
expression levels. It is known that gene mutability negatively corre-
lates with the gene expression level (Hodis et al., 2012; Lawrence
et al., 2013). Since expression of TSs tends to be suppressed in tu-
mors (Wang, Wu, Rajasekaran, & Shin, 2018), this can contribute to a
higher mutability of TSs compared with other genes. Some studies
also indicate that expression directed repair may be important
(Pleasance et al., 2010).
Based on the studied mechanism of UV‐induced mutations
(Bose, 2016; Cadet & Douki, 2018; Dusenbery, McCormick, &
Smith, 1983; Kaplan, 1978), UV light is a principal source of C>T
transitions in pyrimidine dimers. Nevertheless, we cannot completely
rule out a contribution of other sources of mutations including
spontaneous mutagenesis (Ohno, 2019) or the effect of non‐UV
mutagens, for example, temozolomide treatment (Daniel et al., 2019).
In an observational study like this it is impossible to adequately es-
timate effects of different sources of somatic mutations in melanoma.
However, the contribution of sources of mutations other than UV
light in melanoma was shown to be small (Alexandrov et al., 2020;
Birkeland et al., 2018; Phillips, 2018).
We used silent mutations to account for effects of clonal se-
lection when estimating UV sensitivity of individual transcripts. In
contrast to silent mutations, missense mutations are influenced by
both mutability and selection. Consequently, one needs to account
for differences in UV sensitivity when predicting how many mis-
sense mutations one can expect in the transcript. Therefore, the
practical significance of this study relates to the prediction of the
expected number of somatic mutations in genes. The prediction of
the expected number of somatic mutations is essential in identifi-
cation of cancer‐related genes based on the number of somatic
mutations detected in tumor samples (Gorlov et al., 2018; Lawrence
et al., 2013). In cited and other similar studies (Martincorena
et al., 2017; Vineis, 2003) the excess of nonsynonymous mutations
in a gene is used as an indicator of its cancer relevance. The excess
of somatic mutations, however, can also reflect a gene's high in-
herent mutability, for example, abnormally high UV‐sensitivity in
case of melanoma. Thus, differences in UV sensitivity need to be
taken into account when evaluating the expected number of non-
synonymous substitutions in a gene in the analysis of melanoma
samples.
A limitation of our approach is that we may have overestimated
the number of UV‐induced mutations by assuming that all C>T
transitions in pyrimidine dimers are induced by UV light. It is known
that some other factors can also cause C>T transitions in pyrimidine
dimers. Those factors include defects in DNA mismatch repair (Li,
Pearlman, & Hsieh, 2016), error‐prone polymerase POLE (Park &
Pursell, 2019), and alkylating agents (Fu, Calvo, & Samson, 2012).
Indeed, we observed effects of these factors in the analysis of con-
tribution of different mutational signatures (Table 1). The contribu-
tion of these other sources of C>T substitutions to pyrimidine dimers
is, however, small.
In conclusion, we found a substantial variation in UV sensitivity
among human genes and identified gene characteristics associated
with it. Differences in UV sensitivity need to be taken into con-
sideration when predicting how many potentially functional non-
synonymous mutations one can expect to detect in a gene which is
essential step in identification of cancer‐related genes based on the
number of somatic mutations in them.
TABLE 1 Partitioning of genome‐wide screen detected somatic




7 UV light 0.764
23 Unknown (liver cancer) 0.069
1 Age 0.062
10 POLE (ultra‐hypermutation) 0.034
11 Alkylating agents 0.022
12 Unknown (liver cancer) 0.01
17 Unknown (different cancers) 0.009
2 APOBEC 0.008
21 Unknown (stomach cancer/MSI) 0.007
4 Smoking 0.006
3 BRCA1/BRCA2 (failure of DNA
DSBR/large INDELs)
0.005
22 Aristolochic acid 0.004
5 Unknown (all‐cancer types) 0
6 Defective DNA MMR/MSI (small
INDELs)
0
8 Unknown (breast cancer and
medulloblastoma)
0
9 POLH (CLL and BCL) 0
13 APOBEC 0
14 Unknown (uterine cancer and glioma/
hypermutation)
0
15 Defective DNA MMR (small INDELs) 0
16 Unknown (liver cancer) 0
18 Unknown (different cancers) 0
19 Unknown (pilocytic astrocytoma) 0
20 Defective DNA MMR (small INDELs) 0
24 Aflatoxin 0
25 Unknown (Hodgkin lymphoma) 0
26 Defective DNA MMR (small INDELs) 0
27 Unknown (kidney clear cell
carcinomas/small INDELs)
0
28 Unknown (stomach cancer) 0
29 Tobacco chewing 0
30 Unknown (breast cancer) 0
Abbreviation: UV, ultraviolet.
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